2019

    • July 18, 2019

    Nemaura Medical Inc. Appoints Chris Avery as Vice President of Global Business Operations to Support Global Commercial Launch of SugarBEAT®

    Loughborough, England , July 18, 2019 (GLOBE NEWSWIRE) —  Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused...

    Read more
    July 10, 2019

    Nemaura Medical Inc. Submits De Novo 510(k) Application for SugarBEAT® to the U.S. Food and Drug Administration

    Loughborough, England , July 10, 2019 (GLOBE NEWSWIRE) —  Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused...

    Read more
    June 17, 2019

    Nemaura Provides Fiscal 2019 Year-End Business Update

    Readies launch of SugarBEAT® in United Kingdom and Germany following CE Mark approval On track to submit FDA application...

    Read more
    June 14, 2019

    Nemaura Medical Interview to Air on Bloomberg International on the RedChip Money Report

    Loughborough, England, June 14, 2019 (GLOBE NEWSWIRE) —  – Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused...

    Read more
    May 29, 2019

    Nemaura Announces CE Mark Approval of SugarBEAT®

    SugarBEAT® is the World’s First Non-Invasive Continuous Glucose Monitor Loughborough,England, May 29, 2019 (GLOBE NEWSWIRE) — Nemaura Medical, Inc....

    Read more
    May 2, 2019

    Nemaura Announces Open-Source Software for its Continuous Glucose Monitor SugarBEAT®

    Allows 3rd Party Applications to Directly access SugarBEAT® CGM Data Loughborough, England , May 02, 2019 (GLOBE NEWSWIRE) —...

    Read more
    April 23, 2019

    Nemaura Announces Successful Completion of Summative Human Factors Usability Study for SugarBEAT®

    Final step required prior to filing de novo application to the U.S. Food and Drug Administration Loughborough, England ,...

    Read more
    April 18, 2019

    Nemaura Announces Addition of New Predictive Alert Functionality to SugarBEAT®

    Enhances Product Capabilities in Advance of CE Mark Approval April 16, 2019 – Nemaura Medical, Inc. (NASDAQ: NMRD), a...

    Read more
    March 28, 2019

    Nemaura CEO Provides Update to Shareholders

    Announces SugarBEAT® Awaiting CE Mark Approval; On Track for FDA submission in Q2 2019 Loughborough, England, March 28, 2019...

    Read more
    March 12, 2019

    Nemaura Medical Announces Exclusive License and Supply Agreement for SugarBEAT® in the GCC Region

    Loughborough, England , March 12, 2019 (GLOBE NEWSWIRE) — Loughborough, England – March 12, 2019 – Nemaura Medical, Inc....

    Read more